US 12,257,416 B1
Fluid therapy based on sodium excretion, and associated systems, devices, and methods
Andrew V. Halpert, Brookline, MA (US); Antony Jonathan Fields, San Francisco, CA (US); and Jeffrey Testani, New Haven, CT (US)
Assigned to Reprieve Cardiovascular, Inc., Milford, MA (US)
Filed by REPRIEVE CARDIOVASCULAR, INC., Milford, MA (US)
Filed on Sep. 12, 2024, as Appl. No. 18/883,857.
Claims priority of provisional application 63/680,042, filed on Aug. 6, 2024.
Claims priority of provisional application 63/582,218, filed on Sep. 12, 2023.
Int. Cl. A61M 5/14 (2006.01); A61B 5/00 (2006.01); A61B 5/20 (2006.01); A61M 5/172 (2006.01)
CPC A61M 5/1407 (2013.01) [A61B 5/208 (2013.01); A61B 5/4839 (2013.01); A61M 5/1723 (2013.01)] 28 Claims
OG exemplary drawing
 
1. A fluid therapy system, comprising:
a diuretic source configured to provide a diuretic to a patient;
a hydration fluid source configured to provide a hydration fluid to the patient; and
a controller, wherein the controller is configured to—
during a first time period, provide fluid therapy based on an assumed sodium excretion input; and
during a second time period after the first time period—
obtain a sodium excretion input for the patient;
determine a sodium output rate based at least in part on the sodium excretion input; and
based on the sodium output rate, (i) cause the diuretic to be administered to the patient at one or more diuretic dosage rates and (ii) cause the hydration fluid to be administered to the patient at one or more hydration rates to produce a net fluid loss in the patient.